Last update 19 Jun 2025

Admilparant

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
BMS 986278, BMS-986278, BMS-986278-01
Target
Action
antagonists
Mechanism
LPAR1 antagonists(Lysophosphatidic acid receptor Edg-2 antagonists)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC22H31N5O5
InChIKeyUEUNDURNLYLSNB-HOTGVXAUSA-N
CAS Registry2170126-74-4

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Progressive fibrotic interstitial lung diseasePhase 3
United States
25 Oct 2023
Progressive fibrotic interstitial lung diseasePhase 3
China
25 Oct 2023
Progressive fibrotic interstitial lung diseasePhase 3
Japan
25 Oct 2023
Progressive fibrotic interstitial lung diseasePhase 3
Argentina
25 Oct 2023
Progressive fibrotic interstitial lung diseasePhase 3
Australia
25 Oct 2023
Progressive fibrotic interstitial lung diseasePhase 3
Austria
25 Oct 2023
Progressive fibrotic interstitial lung diseasePhase 3
Belgium
25 Oct 2023
Progressive fibrotic interstitial lung diseasePhase 3
Brazil
25 Oct 2023
Progressive fibrotic interstitial lung diseasePhase 3
Canada
25 Oct 2023
Progressive fibrotic interstitial lung diseasePhase 3
Chile
25 Oct 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
tmmbhzxoth(qwnhkvintb) = observed in 13/42 (31.0%) patients gcisbnlrsy (fdvkgcyunq )
Positive
16 May 2025
Phase 2
-
rwlmurbvzk(ymdfavdbut) = Diarrhea occurred at similar frequencies in admilparant arms versus placebo qkonzcgvsf (znfbimcigh )
Positive
11 Oct 2024
Phase 2
122
rorpjozfhj(rbdtcvkaex) = nqkimaomhv jopotfhoxv (ojyqgiszvc )
Positive
09 Sep 2023
rorpjozfhj(rbdtcvkaex) = qpivzvahdb jopotfhoxv (ojyqgiszvc )
Phase 2
276
waqlpcdbfy(dgqawawbfg) = efqeudmcak ejsedeofpi (ecifuaumih, -1.8 to 1.4)
Met
Positive
22 May 2023
waqlpcdbfy(dgqawawbfg) = fwocdinbei ejsedeofpi (ecifuaumih, -0.1 to 3.0)
Met
Not Applicable
-
BMS-986278 30mg
nleobrhokn(izrkagzwtf) = 5%, 8%, 11% ewluebkehw (vtdymrecmy )
-
21 May 2023
BMS-986278 60mg
Phase 2
278
afydubqpkl(cycjzqoksr) = yrxbmdzyki nlpvrsremo (vbgkunjxuq )
-
28 Oct 2021
Not Applicable
-
15
wclrwvmwdn(ctzzcthkut) = wpnxnnfoxs qdntpqpkdt (kyjnosfqzq )
-
07 Sep 2020
Phase 1
-
-
rewvkhrfqu(jparwnslbh) = the most common AE was headache mpydeoltnx (hahampfhcf )
Positive
28 Sep 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free